How the multi-region Top 300 was constructed
There is no single official 300-company table covering all included regions. The atlas combines national industry directories, regulatory registers and established manufacturing participants, then separates leaders from an extended manufacturing selection.
China, India, Israel, the USA and the EU/Switzerland/United Kingdom scope are excluded because separate FUZKK atlases already cover them.
| Range | Tier | Basis | Interpretation |
|---|---|---|---|
| 1–100 | FUZKK atlas leaders | Major regional pharma, biologics, vaccines, API/CDMO and generics | Atlas priority, not a single official revenue ranking. |
| 101–300 | Extended manufacturing selection | Manufacturers and specialty companies from national ecosystems | Extends geographical and technological coverage. |
| All positions | FUZKK fit | Product/API, Lumex, LabEx and Medical Devices | Potential applicability rather than actual deployment. |
Public sources
- JPMA — Japanese R&D-oriented pharmaceutical companies
- KPBMA — South Korean manufacturers
- APAC — Asia-Pacific national industry associations
- SFDA — registered drug companies and licensed establishments
- İEİS — the Turkish pharmaceutical industry
- PPMA — Pakistan's pharmaceutical manufacturing industry
- SLPMA — local manufacturers in Sri Lanka
- Health Canada — Drug Establishment Licences
- TGA — licensed manufacturers in Australia
- SAHPRA — active pharma licensed establishments
- Egyptian Drug Authority — regulatory and product context
What the atlas does not claim
- positions 1–300 do not form a single official revenue ranking;
- industry-association membership does not replace current licence verification;
- a registration or product directory does not confirm a specific installed equipment model;
- the atlas does not claim actual use of FUZKK;
- the proposed utility set must be validated for the specific product and site.